Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical sirolimus for prevention of keratinocyte cancer in solid organ transplant recipients
ACTRN12618001961235Phase 2Completed
- Sponsor
- University of Queensland Diamantina Institute
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of sirolimus in keratinocyte carcinoma, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), sponsored by University of Queensland Diamantina Institute. Primary endpoint: Composite change in surface area and number of keratotic lesions. Started Jan 2019; status: completed.
02
Drugs
sirolimus
03
Conditions
keratinocyte carcinomabasal cell carcinoma (BCC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on ACTRN12618001961235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001961235.